These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23722323)

  • 1. Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome.
    Orbach R; Gurevich M; Achiron A
    Mult Scler; 2014 Jan; 20(1):35-42. PubMed ID: 23722323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.
    Tumani H; Lehmensiek V; Rau D; Guttmann I; Tauscher G; Mogel H; Palm C; Hirt V; Suessmuth SD; Sapunova-Meier I; Ludolph AC; Brettschneider J
    Neurosci Lett; 2009 Mar; 452(2):214-7. PubMed ID: 19383442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis.
    Antonelou RCh; Emmanouilidou E; Gasparinatos G; Velona T; Voumvourakis KI; Stefanis L
    J Neurochem; 2015 Aug; 134(4):748-55. PubMed ID: 25962981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
    PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome.
    Sladkova V; Mareš J; Lubenova B; Zapletalova J; Stejskal D; Hlustik P; Kanovsky P
    Neurol Res; 2011 May; 33(4):415-20. PubMed ID: 21535941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or relapsing-remitting multiple sclerosis.
    Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Sfagos C
    J Neuroendocrinol; 2010 Jun; 22(6):503-8. PubMed ID: 20236233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic relevance of the C-X-C motif chemokine ligand 13 and interleukin-8 in predicting the transition from clinically isolated syndrome to multiple sclerosis.
    Klíčová K; Mareš J; Sobek O; Rous Z; Rous M; Raška M; Hartung HP
    Eur J Neurosci; 2024 Jun; 59(11):2955-2966. PubMed ID: 38453679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
    Ahlbrecht J; Martino F; Pul R; Skripuletz T; Sühs KW; Schauerte C; Yildiz Ö; Trebst C; Tasto L; Thum S; Pfanne A; Roesler R; Lauda F; Hecker M; Zettl UK; Tumani H; Thum T; Stangel M
    Mult Scler; 2016 Aug; 22(9):1202-14. PubMed ID: 26493127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
    Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
    Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course.
    Sbardella E; Greco A; Stromillo ML; Prosperini L; Puopolo M; Cefaro LA; Pantano P; De Stefano N; Minghetti L; Pozzilli C
    Mult Scler; 2013 Apr; 19(4):411-7. PubMed ID: 22917691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.
    Komori M; Matsuyama Y; Nirasawa T; Thiele H; Becker M; Alexandrov T; Saida T; Tanaka M; Matsuo H; Tomimoto H; Takahashi R; Tashiro K; Ikegawa M; Kondo T
    Ann Neurol; 2012 May; 71(5):614-23. PubMed ID: 22522477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis.
    Gajofatto A; Bongianni M; Zanusso G; Bianchi MR; Turatti M; Benedetti MD; Monaco S
    Acta Neurol Scand; 2013 Nov; 128(5):336-44. PubMed ID: 23550839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients.
    Valis M; Talab R; Stourac P; Andrys C; Masopust J
    Neuro Endocrinol Lett; 2008 Dec; 29(6):971-6. PubMed ID: 19112391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.
    Verbeek MM; Notting EA; Faas B; Claessens-Linskens R; Jongen PJ
    Acta Neurol Scand; 2010 May; 121(5):309-14. PubMed ID: 19925532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of semaphorin 7A and ala-β-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis.
    Cantó E; Tintoré M; Villar LM; Borrás E; Alvarez-Cermeño JC; Chiva C; Sabidó E; Rovira A; Montalban X; Comabella M
    J Neuroinflammation; 2014 Nov; 11():181. PubMed ID: 25406498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
    Khademi M; Kockum I; Andersson ML; Iacobaeus E; Brundin L; Sellebjerg F; Hillert J; Piehl F; Olsson T
    Mult Scler; 2011 Mar; 17(3):335-43. PubMed ID: 21135023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis.
    Dong-Si T; Weber J; Liu YB; Buhmann C; Bauer H; Bendl C; Schnitzler P; Grond-Ginsbach C; Grau AJ
    J Neurol; 2004 May; 251(5):542-7. PubMed ID: 15164186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
    Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.